OBJECTIVE: Thirty-six months of isoniazid preventive therapy (36IPT) was superior to 6 months of IPT (6IPT) in preventing tuberculosis (TB) among HIV-infected adults in Botswana. We assessed the posttrial durability of this benefit. DESIGN: A 36-month double-blind placebo controlled trial (1 : 1 randomization) with recruitment between November 2004 and July 2006 and observation until June 2011. METHODS:One thousand, nine hundred and ninety-five participants were followed in eight public health clinics. Twenty-four percent had a tuberculin skin test ≥5 mm (TST-positive). A minimum CD4 lymphocyte count was not required for enrolment. Antiretroviral therapy (ART) was provided in accordance with Botswana guidelines; 72% of participants retained by June 2011 had initiated ART. Multivariable analysis using Cox regression analysis included treatment arm, TST status, ART as a time-dependent variable and CD4 cell count at baseline and updated at 36 months. RESULTS: In the posttrial period, 2.13 and 2.14 per 100 person-years accumulated, whereas 0.93 and 1.13% TB incidence rates were observed in the 36IPT and 6IPT arms, respectively (P = 0.52). The crude hazard ratio of TB during the trial and posttrial was 0.57 [95% confidence intervals (CI) 0.33, 0.99] and 0.82 (95% CI 0.46, 1.49), and when restricted to TST-positive participants was 0.26 (95% CI 0.08, 0.80) and 0.40 (95% CI 0.15, 1.08), respectively. Multivariable analysis showed that ART use was associated with reduced death (adjusted hazard ratio 0.36, 95% CI 0.17-0.75) but not TB (0.92, 95% CI 0.55-1.53) in the posttrial period. CONCLUSION: The benefit of 36IPT for TB prevention declined posttrial in this cohort. Adjunctive measures are warranted to prevent TB among HIV-infected persons receiving long-term ART in TB-endemic settings.
RCT Entities:
OBJECTIVE: Thirty-six months of isoniazid preventive therapy (36IPT) was superior to 6 months of IPT (6IPT) in preventing tuberculosis (TB) among HIV-infected adults in Botswana. We assessed the posttrial durability of this benefit. DESIGN: A 36-month double-blind placebo controlled trial (1 : 1 randomization) with recruitment between November 2004 and July 2006 and observation until June 2011. METHODS: One thousand, nine hundred and ninety-five participants were followed in eight public health clinics. Twenty-four percent had a tuberculin skin test ≥5 mm (TST-positive). A minimum CD4 lymphocyte count was not required for enrolment. Antiretroviral therapy (ART) was provided in accordance with Botswana guidelines; 72% of participants retained by June 2011 had initiated ART. Multivariable analysis using Cox regression analysis included treatment arm, TST status, ART as a time-dependent variable and CD4 cell count at baseline and updated at 36 months. RESULTS: In the posttrial period, 2.13 and 2.14 per 100 person-years accumulated, whereas 0.93 and 1.13% TB incidence rates were observed in the 36IPT and 6IPT arms, respectively (P = 0.52). The crude hazard ratio of TB during the trial and posttrial was 0.57 [95% confidence intervals (CI) 0.33, 0.99] and 0.82 (95% CI 0.46, 1.49), and when restricted to TST-positive participants was 0.26 (95% CI 0.08, 0.80) and 0.40 (95% CI 0.15, 1.08), respectively. Multivariable analysis showed that ART use was associated with reduced death (adjusted hazard ratio 0.36, 95% CI 0.17-0.75) but not TB (0.92, 95% CI 0.55-1.53) in the posttrial period. CONCLUSION: The benefit of 36IPT for TB prevention declined posttrial in this cohort. Adjunctive measures are warranted to prevent TB among HIV-infectedpersons receiving long-term ART in TB-endemic settings.
Authors: April C Pettit; Cathy A Jenkins; Samuel E Stinnette; Peter F Rebeiro; Robert B Blackwell; Stephen P Raffanti; Bryan E Shepherd; Timothy R Sterling Journal: J Acquir Immune Defic Syndr Date: 2011-08-01 Impact factor: 3.731
Authors: C Kabali; C F von Reyn; D R Brooks; R Waddell; L Mtei; M Bakari; M Matee; K Pallangyo; R D Arbeit; C R Horsburgh Journal: Int J Tuberc Lung Dis Date: 2011-11 Impact factor: 2.373
Authors: Sabine M Hermans; Agnes N Kiragga; Petra Schaefer; Andrew Kambugu; Andy I M Hoepelman; Yukari C Manabe Journal: PLoS One Date: 2010-05-07 Impact factor: 3.240
Authors: Gavin J Churchyard; Katherine L Fielding; James J Lewis; Leonie Coetzee; Elizabeth L Corbett; Peter Godfrey-Faussett; Richard J Hayes; Richard E Chaisson; Alison D Grant Journal: N Engl J Med Date: 2014-01-23 Impact factor: 91.245
Authors: Amitabh B Suthar; Stephen D Lawn; Julia del Amo; Haileyesus Getahun; Christopher Dye; Delphine Sculier; Timothy R Sterling; Richard E Chaisson; Brian G Williams; Anthony D Harries; Reuben M Granich Journal: PLoS Med Date: 2012-07-24 Impact factor: 11.069
Authors: Susan Swindells; Ritesh Ramchandani; Amita Gupta; Constance A Benson; Jorge Leon-Cruz; Noluthando Mwelase; Marc A Jean Juste; Javier R Lama; Javier Valencia; Ayotunde Omoz-Oarhe; Khuanchai Supparatpinyo; Gaerolwe Masheto; Lerato Mohapi; Rodrigo O da Silva Escada; Sajeeda Mawlana; Peter Banda; Patrice Severe; James Hakim; Cecilia Kanyama; Deborah Langat; Laura Moran; Janet Andersen; Courtney V Fletcher; Eric Nuermberger; Richard E Chaisson Journal: N Engl J Med Date: 2019-03-14 Impact factor: 91.245
Authors: Ethan D Valinetz; Daniel Matemo; Jill K Gersh; Lara L Joudeh; Simon C Mendelsohn; Thomas J Scriba; Mark Hatherill; John Kinuthia; Anna Wald; Gerard A Cangelosi; Ruanne V Barnabas; Thomas R Hawn; David J Horne Journal: AIDS Date: 2022-05-25 Impact factor: 4.632
Authors: Andrew Kazibwe; Bonniface Oryokot; Levicatus Mugenyi; David Kagimu; Abraham Ignatius Oluka; Darlius Kato; Simple Ouma; Edmund Tayebwakushaba; Charles Odoi; Kizito Kakumba; Ronald Opito; Ceasar Godfrey Mafabi; Michael Ochwo; Robert Nkabala; Wilber Tusiimire; Agnes Kateeba Tusiime; Sarah Barbara Alinga; Yunus Miya; Michael Bernard Etukoit; Irene Andia Biraro; Bruce Kirenga Journal: PLoS One Date: 2022-05-16 Impact factor: 3.752
Authors: I Pathmanathan; S Ahmedov; E Pevzner; G Anyalechi; S Modi; H Kirking; J S Cavanaugh Journal: Int J Tuberc Lung Dis Date: 2018-06-01 Impact factor: 2.373
Authors: Lukas Fenner; Andrew Atkinson; Andrew Boulle; Matthew P Fox; Hans Prozesky; Kathrin Zürcher; Marie Ballif; Hansjakob Furrer; Marcel Zwahlen; Mary-Ann Davies; Matthias Egger Journal: J Int AIDS Soc Date: 2017-06-23 Impact factor: 5.396
Authors: Masanja Robert; Jim Todd; Bernard J Ngowi; Sia E Msuya; Angella Ramadhani; Veryhel Sambu; Isaya Jerry; Martin R Mujuni; Michael J Mahande; James S Ngocho; Werner Maokola Journal: BMC Infect Dis Date: 2020-04-10 Impact factor: 3.090